The Latest SPAC News and Rumors: November 1, 2021


The Latest SPAC News and Rumors: November 1, 2021

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Prison phone company Securus in talks to merge with Atlantic Avenue, Redbox signs content deal with Fremantle, and Singapore’s Novo Tellus files for blank-check IPO

Prison Phone Company Securus Is in SPAC Merger Talks

Tom Gores’s Platinum Equity is exploring strategic options for one of its most controversial investments, prison phone operator Securus Technologies Inc., and is in talks to take it public through a merger with a blank-check company, according to Bloomberg.

Atlantic Avenue Acquisition Corp. (NYSE:ASAQ), formed by middle-market lender MC Credit Partners, has approached Platinum about a potential deal to merge with Securus.


Redbox Signs Content Deal With Fremantle to Further Rapid Expansion of Free Streaming Service

Redbox (NASDAQ:RDBX), a leading entertainment company, today announced it has signed a content deal with Fremantle to further accelerate the company’s free streaming service. The deal adds Free Ad Supported Television (FAST) channels which will make their debut on December 1. They include BUZZR, The Price Is Right: The Barker Era and the Baywatch channel.

Seaport Global Acquisition Corp. secured shareholder approval of its combination with home entertainment provider Redbox in a special meeting on October 21.


Singapore’s Novo Tellus Files for Blank-Check IPO

Singapore buyout firm Novo Tellus Capital Partners has applied to list a SPAC with the city-state’s exchange, according to Bloomberg.

The technology and industrials-focused firm is planning to raise between S$200 million ($148 million) and S$250 million through an IPO of the blank-check company. The IPO could take place as soon as the end of this year.


Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID

Revelation Biosciences Inc., a clinical-stage life sciences company that is focused on the development of immunologic based therapies and diagnostics for the prevention and treatment of disease, announced today that it has engaged MedWorld Advisors to optimize the value of Revelation’s diagnostic tool, REVID™.

Revelation recently announced that it has entered into a definitive merger agreement with Petra Acquisition, Inc. (NASDAQ:PAIC) for a business combination that will result in Revelation becoming a publicly traded company. The merger is expected to close in Q4 2021.